Vegzelma is a vascular endothelial growth factor inhibitor.
Drugs in the Pipeline
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Bevacizumab-awwb 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
The approval was based on data from the phase 3 KEYNOTE-826 trial.
ESMO 2021, News
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.